Health & Longevity
FDA Approves Novartis's Rhapsido as First Drug for Symptomatic Dermographism
The oral BTK inhibitor wins a second US indication on a phase 3 cohort in which 29.3% of treated patients, versus 14.0% on placebo, cleared their hives at week 12.
·5 min read